BlackRock submits revised S-1 file for Ethereum ETF, disclosing information related to seed fund
BlackRock has submitted a revised S-1 registration statement for the proposed Ethereum ETF, disclosing information about seed fund investors. BlackRock stated in the revised document: "On May 21, 2024, seed relief fund investors conditionally purchased 400,000 shares of Seed Creation Basket at a price equivalent to $25 per share." BlackRock also said that these shares will be listed and traded under the code "ETHA". The U.S. Securities and Exchange Commission (SEC) recently began discussions with issuers on Form S-1. Some analysts speculate that this process may take several weeks. Bloomberg ETF analyst Eric Balchunas tweeted on Wednesday that BlackRock's amended S-1 is a "good sign". Launching an Ethereum ETF by the end of June is a reasonable possibility, but analysts still believe that the Ethereum ETF will launch on July 4th.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$40 billion in bond issuance with a maximum interest rate of 8.3%! SpaceX (SPCX.US) AI gamble also exposes the “funding winter” for AI infrastructure
According to media reports citing sources familiar with the matter, SpaceX is preparing to complete a debt issuance totaling $40 billion, with an interest rate significantly higher than previous borrowing costs, reflecting growing investor concerns over financing for artificial intelligence (AI) infrastructure.
Tom Lee: The market is in a sell-off state, and tech stocks have reached support levels
TS Lombard scenario analysis: An AI bubble burst could trigger a 30% plunge in the S&P 500, wiping out 20 trillion dollars in market value—but don't rush to short!
Dario Perkins from TS Lombard predicted in a scenario analysis released on Thursday that if AI capital expenditure collapses, approximately $20 trillions in U.S. stock market value could evaporate, triggering credit losses of $125 billions to $190 billions.
Gilead Sciences (GILD.US) acquires PepStar’s oral inflammation drug program for $1.275 billion in cash, increasing investment in inflammatory bowel disease pipeline
Gilead Sciences will acquire PepStar’s anti-inflammatory drug program for $1.28 billions.
Crypto prices
More
